The company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor, AndexXa (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable factor Xa inhibitor, and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers.

Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions.